Sacubitril/valsartan in heart failure and end‐stage renal insufficiency

Heyse, Alex; Manhaeghe, Lynn; Mahieu, Elien; Vanfraechem, Céline; Durme, Frederik Van

doi:10.1002/ehf2.12544

Cited by 24 publications

(17 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…What is interesting, it is also proven that the therapy with valsartan significantly increases the long-term quality of life in patients with chronic heart failure [74], which is a result of biochemical, echocardiographic, and clinical improvements [75]. Simultaneously, the drug remains safe in patients with many comorbidities, especially in chronic kidney disease [76]. In patients with hypertension, the use of valsartan is also associated with the reduction of the risk of organ complications, including left ventricular hypertrophy [77,78].…”

mentioning

confidence: 99%

Pleiotropic Properties of Valsartan: Do They Result from the Antiglycooxidant Activity? Literature Review and In Vitro Study

Mil

Gryciuk

Pawlukianiec

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Valsartan belongs to angiotensin II type 1 (AT1) receptor blockers (ARB) used in cardiovascular diseases like heart failure and hypertension. Except for its AT1-antagonism, another mechanism of drug action has been suggested in recent research. One of the supposed actions refers to the positive impact on redox balance and reducing protein glycation. Our study is aimed at assessing the antiglycooxidant properties of valsartan in an in vitro model of oxidized bovine serum albumin (BSA). Glucose, fructose, ribose, glyoxal (GO), methylglyoxal (MGO), and chloramine T were used as glycation or oxidation agents. Protein oxidation products (total thiols, protein carbonyls (PC), and advanced oxidation protein products (AOPP)), glycooxidation products (tryptophan, kynurenine, N-formylkynurenine, and dityrosine), glycation products (amyloid-β structure, fructosamine, and advanced glycation end products (AGE)), and albumin antioxidant activity (total antioxidant capacity (TAC), DPPH assay, and ferric reducing antioxidant power (FRAP)) were measured in each sample. In the presence of valsartan, concentrations of protein oxidation and glycation products were significantly lower comparing to control. Moreover, albumin antioxidant activity was significantly higher in those samples. The drug’s action was comparable to renowned antiglycation agents and antioxidants, e.g., aminoguanidine, metformin, Trolox, N-acetylcysteine, or alpha-lipoic acid. The conducted experiment proves that valsartan can ameliorate protein glycation and oxidation in vitro in various conditions. Available animal and clinical studies uphold this statement, but further research is needed to confirm it, as reduction of protein oxidation and glycation may prevent cardiovascular disease development.

show abstract

mentioning

confidence: 99%

Pleiotropic Properties of Valsartan: Do They Result from the Antiglycooxidant Activity? Literature Review and In Vitro Study

Mil

Gryciuk

Pawlukianiec

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…After initiation of sacubitril/valsartan, there was a symptomatic improvement with a clear reduction NT-proBNP, accompanied by a decrease in filling pressures [11] A retrospective study analysed the clinical and laboratory data of 23 HFrEF patients, found that sacubitril/valsartan could reduce the hsTnT (high-sensitive troponin) and sST2 (soluble ST2) levels and improve LVEF in HFrEF patients with ESRD, which is the first study to show the effectiveness and safety of sacubitril/valsartan in ESRD patients with HFrEF [10].…”

Section: Case Reports In Clinical Medicinementioning

confidence: 96%

The Effect of Sacubitril/Valsartan in a Dialysis Patient with Severe Heart Failure

Kong¹,

Yu²,

Wang³

et al. 2021

CRCM

View full text Add to dashboard Cite

Heart failure (HF) is a major comorbidity in patients with end-stage renal disease (ESRD). The pathogenesis of HF in patients on renal replacement therapy represents the confluence of several traditional and nontraditional vascular risk factors, unique to the milieu of chronic kidney disease and the dialysis modality [1]. The purpose of this report is to describe the efficacy and safety of sacubitril/valsartan for an ESRD patient on hemodialysis therapy conmbined with heart failure with reduced ejection fraction (HFrEF). A 35-year-old woman was undergoing hemodialysis due to ESRD and suffering from heart failure with reduced ejection fraction. Because of worsening heart failure and hypertension, she was prescribed with sacubitril/valsartan at a dose of 50 mg twice a day, spironolactone at a dose of 20 mg three times a day and metoprolol at a dose of 23.75 mg once daily. There was a symptomatic improvement with the heart failure and reduction in NT-proBNP level, accompanied by a decrease of blood pressure after using sacubitric/valsartan. In conclusion, it is safe and effective to take sacubitril/valsartan in this hemodialysis patient with severe heart failure.

show abstract

“…There have been a few studies published on the use of sacubitril/valsartan in patients with stage 4 or 5 CKD, or There is a paucity of data on the evidence of ARNI in patients with ESRD on maintenance dialysis. Heyse et al [56] presented a case report of a 67-year-old man with HFrEF due to ischemic cardiomyopathy and renal insufficiency undergoing hemodialysis, who tolerated a moderate dose of 49/51 mg twice daily, and finally showed symptomatic improvement with a reduction in HF biomarkers and left ventricular filling pressure. Only one study evaluated the use of sacubitril/valsartan in patients with HFrEF and ESRD, which showed that sacubitril/valsartan reduced cardiac biomarkers and improved LVEF; the most common adverse event was hypotension, which was corrected with down-titration of the drug dosage [57].…”

Section: Efficacy and Safety Of Angiotensin Receptorneprilysin Inhibitor In Advanced Chronic Kidney Diseasementioning

confidence: 99%

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease

Cho

Kang

2021

Kidney Res Clin Pract

View full text Add to dashboard Cite

Despite significant advances in the management of heart failure with reduced ejection fraction (HFrEF), there remains an enormous health problem with high morbidity and mortality over the last few decades. The neprilysin inhibitor enhances the activity of natriuretic peptides, producing vasodilation, natriuresis, and diuresis. Angiotensin receptor blockers inhibit the renin-angiotensin-aldosterone system. Sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to improve cardiovascular outcomes in HFrEF and delay the progression of chronic kidney disease (CKD) in patients with HFrEF. The PARADIGM-HF study showed a reduction in diuretic need in the ARNI group. While the use of diuretics is effective in volume control in patients with HFrEF, their use has the potential to adversely affect renal function. Therefore, ARNI therapy could benefit patients with heart failure and CKD by reducing cardiovascular morbidity and mortality and possibly retarding the progression of CKD, although more clinical evidence is required in patients with severe CKD and end-stage renal disease.

show abstract

Sacubitril/valsartan in heart failure and end‐stage renal insufficiency

Cited by 24 publications

References 5 publications

Pleiotropic Properties of Valsartan: Do They Result from the Antiglycooxidant Activity? Literature Review and In Vitro Study

Pleiotropic Properties of Valsartan: Do They Result from the Antiglycooxidant Activity? Literature Review and In Vitro Study

The Effect of Sacubitril/Valsartan in a Dialysis Patient with Severe Heart Failure

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease

Contact Info

Product

Resources

About